was read the article
array:24 [ "pii" => "S1646343916300232" "issn" => "16463439" "doi" => "10.1016/j.rpedm.2016.06.003" "estado" => "S300" "fechaPublicacion" => "2016-07-01" "aid" => "130" "copyright" => "Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo" "copyrightAnyo" => "2016" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Rev Port Endocrinol Diabetes Metab. 2016;11:197-201" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3309 "formatos" => array:3 [ "EPUB" => 220 "HTML" => 2369 "PDF" => 720 ] ] "itemSiguiente" => array:19 [ "pii" => "S1646343915000413" "issn" => "16463439" "doi" => "10.1016/j.rpedm.2015.10.002" "estado" => "S300" "fechaPublicacion" => "2016-07-01" "aid" => "103" "copyright" => "Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Rev Port Endocrinol Diabetes Metab. 2016;11:202-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 8000 "formatos" => array:3 [ "EPUB" => 194 "HTML" => 6836 "PDF" => 970 ] ] "pt" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Caso clínico</span>" "titulo" => "Prolactinoma gigante – 3 casos clínicos e revisão da literatura" "tienePdf" => "pt" "tieneTextoCompleto" => "pt" "tieneResumen" => array:2 [ 0 => "pt" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "202" "paginaFinal" => "207" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Giant prolactinoma ‐ Three case reports and literature review" ] ] "contieneResumen" => array:2 [ "pt" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "pt" => true ] "contienePdf" => array:1 [ "pt" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figura 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1211 "Ancho" => 1000 "Tamanyo" => 125143 ] ] "descripcion" => array:1 [ "pt" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">RMN T2 corte coronal. Lesão expansiva extra‐axial, com ponto de partida selar, mais evidente à esquerda.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Patrícia Tavares, Gustavo Rocha, Mário Resende, Lino Mascarenhas, Maria João Oliveira" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Patrícia" "apellidos" => "Tavares" ] 1 => array:2 [ "nombre" => "Gustavo" "apellidos" => "Rocha" ] 2 => array:2 [ "nombre" => "Mário" "apellidos" => "Resende" ] 3 => array:2 [ "nombre" => "Lino" "apellidos" => "Mascarenhas" ] 4 => array:2 [ "nombre" => "Maria João" "apellidos" => "Oliveira" ] ] ] ] ] "idiomaDefecto" => "pt" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1646343915000413?idApp=UINPBA00004N" "url" => "/16463439/0000001100000002/v1_201607230344/S1646343915000413/v1_201607230344/pt/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1646343916300049" "issn" => "16463439" "doi" => "10.1016/j.rpedm.2016.05.001" "estado" => "S300" "fechaPublicacion" => "2016-07-01" "aid" => "125" "copyright" => "Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Rev Port Endocrinol Diabetes Metab. 2016;11:188-96" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4920 "formatos" => array:3 [ "EPUB" => 254 "HTML" => 3567 "PDF" => 1099 ] ] "pt" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Artigo original</span>" "titulo" => "Determinantes do estado de saúde dos diabéticos" "tienePdf" => "pt" "tieneTextoCompleto" => "pt" "tieneResumen" => array:2 [ 0 => "pt" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "188" "paginaFinal" => "196" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Determinants of diabetic's health status" ] ] "contieneResumen" => array:2 [ "pt" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "pt" => true ] "contienePdf" => array:1 [ "pt" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Rui Santos Cruz, Catarina Elisabete Leitão, Pedro Lopes Ferreira" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Rui" "apellidos" => "Santos Cruz" ] 1 => array:2 [ "nombre" => "Catarina Elisabete" "apellidos" => "Leitão" ] 2 => array:2 [ "nombre" => "Pedro" "apellidos" => "Lopes Ferreira" ] ] ] ] ] "idiomaDefecto" => "pt" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1646343916300049?idApp=UINPBA00004N" "url" => "/16463439/0000001100000002/v1_201607230344/S1646343916300049/v1_201607230344/pt/main.assets" ] "en" => array:18 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Lipid profile and persistent lipid abnormalities in diabetic patients – a retrospective study" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "197" "paginaFinal" => "201" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Ana Margarida Monteiro, Isabel Palma" "autores" => array:2 [ 0 => array:4 [ "nombre" => "Ana Margarida" "apellidos" => "Monteiro" "email" => array:2 [ 0 => "anamargaridacmonteiro@gmail.com" 1 => "ana.m.monteiro@hospitaldebraga.pt" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Isabel" "apellidos" => "Palma" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Department of Endocrinology, Hospital de Braga, Braga, Portugal" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Department of Endocrinology, Centro Hospitalar do Porto, Porto, Portugal" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Perfil lipídico e persistência de anomalias lipídicas em doentes diabéticos – um estudo retrospetivo" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Cardiovascular disease (CVD) is the leading cause of death among adult diabetic patients.<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">1</span></a> Although the multifactorial etiology of atherosclerotic vascular disease, dyslipidemia is a common and an important predictor of cardiovascular risk.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">2</span></a> Dyslipidemia is usually present at diagnosis of type 2 diabetes and persists regardless of the treatment of hyperglycemia. The main therapy goal in the management of dyslipidemia is to decrease the levels of LDL-cholesterol (LDL-C) and other apolipoprotein-B-containing lipoproteins, which is primarily achieved with dietary modifications and statins.<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">3,4</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Data from randomized controlled trials of statin therapy show highly significant reductions in the incidence of major CVD events in diabetic patients, with or without established CVD. Moreover, the reductions in major CVD events are proportional to the reduction in LDL cholesterol. Despite the widespread evidence of the benefits of lipid-lowering treatment, particularly with statins, for reducing cardiovascular disease and mortality in diabetic patients, a considerable proportion of diabetic patients do not achieve the therapeutic goals in LDL cholesterol.<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">5,6</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">The aim of this study is to characterize lipid profile of diabetic patients, according the presence or absence of previous cardiovascular event and the evaluation of the suitability of the treatment with statins according to the cardiovascular profile. Additionally, our purpose is to determine in the statin-treated patients, the prevalence of persistent lipid abnormalities.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Material and methods</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Data sources and subjects</span><p id="par0020" class="elsevierStylePara elsevierViewall">This article describes an observational, analytical and retrospective study of outpatient diabetic patients followed at Educational Therapy of Diabetes Consultation (CTED) in <span class="elsevierStyleItalic">Centro Hospitalar do Porto</span> (CHP), between June 2014 and June 2015. CTED is a multidisplinary consultation composed of endocrinologists, nurses, nutritionists, psychologists and podiatrists. The main purpose of this consult is diabetes self-management education and support. The patients are referenced to this consult by family physician or by another specialty consultation in HSA.</p><p id="par0025" class="elsevierStylePara elsevierViewall">Outpatients eligible for inclusion were age ≥18 years old. Patients were excluded if they were type 1 diabetic and if was impossible to obtain the file of the patient. The source of information was electronic or paper file.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Data collection</span><p id="par0030" class="elsevierStylePara elsevierViewall">Data were collected from medical records and clinical examination at the time of the consults. Demographics (age and gender) and anthropometric variables [weight, height and body mass index (BMI)] were recorded at first visit, as well as glycosylated hemoglobin (DCA2000 method). Lipid profile [total cholesterol (TC), triglycerides (TG), LDL-C, HDL-cholesterol (HDL-C) and apolipoprotein B (apoB)] were obtained on the second visit. The measurements were made in the same laboratory, by standard hospital assays – CT, HDL-C and TG through enzymatic methods (Roche®) in freshly drawn lithium-heparin plasma samples. The value of LDL-C was calculated using the Friedewald equation (LDL-C<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>TC-HDL-C-[TG/5]), if TG levels <400<span class="elsevierStyleHsp" style=""></span>mg/dl and measured directly at higher levels. Non-HDL cholesterol (non HDL-C) was also calculated (TC-HDL-C). Apolipoproteins were measured through immunoturbidimetric assays. Because of its influence on lipid profile, we excluded thyroid dysfunction in all patients through TSH measurement by electrochemiluminescence.</p><p id="par0035" class="elsevierStylePara elsevierViewall">The presence of cardiovascular risk factors (smoking, hypertension, dyslipidemia and physical inactivity), of diabetic kidney disease and history of cardiovascular disease (ischemic heart disease, cerebrovascular disease and peripheral artery disease) were registered.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Definition of dyslipidemia</span><p id="par0040" class="elsevierStylePara elsevierViewall">To determine the persistence of lipid abnormalities, in terms of dyslipidemia treatment and goals of lipid levels, it was applied the American Diabetes Association (ADA) recommendations of 2014. Accordingly, patients without overt CVD the goal of LDL-C is less than 100<span class="elsevierStyleHsp" style=""></span>mg/dl, and in individuals with overt CVD the goal of LDL-C is less than 70<span class="elsevierStyleHsp" style=""></span>mg/dl. Although the LDL-target statin therapy is the preferred strategy, additional targets are triglyceride levels less than 150<span class="elsevierStyleHsp" style=""></span>mg/dl and HDL-C superior to 40 or 50<span class="elsevierStyleHsp" style=""></span>mg/dl, in men and women, respectively.<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">7</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall">The lipid levels goals correspond to a range of values defined by an upper limit without a lower limit. Although the term target is commonly used interchangeably, achieving targets could result in the undertreatment of many patients who could benefit from having LDL-C, triglyceride values below the target values or HDL-C above the target value.</p><p id="par0050" class="elsevierStylePara elsevierViewall">To analyze the suitability of the dose of statins were used the recommendations of the ADA in 2015. Therefore, diabetic patients were divided in groups considering the age and the presence or absence of overt CVD [previous cardiovascular events or acute coronary syndromes] and cardiovascular (CV) risk factors [LDL<span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>100<span class="elsevierStyleHsp" style=""></span>mg/dl, high blood pressure, smoking, overweight or obesity]. Patients of all ages with diabetes and overt CVD should be medicated with an high-dose statin. Patients with diabetes under 40 years of age and with additional CVD risk factors, it should be considered using moderate or high-dose statin. For patients with diabetes aged 40–75 years without additional CVD risk factors, it should be considered using moderate-dose statin. For patients with diabetes aged 40–75 years with additional CVD risk factors, it should be considered using high-dose statin. For diabetics over 75 years old without additional CVD risk factors, it should be considered using moderate-dose statin therapy. And for patients over 75 years with additional CVD risk factors, it should be considered using moderate or high-dose statin therapy.<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">8</span></a></p><p id="par0055" class="elsevierStylePara elsevierViewall">The statins were classified in high-intensity and moderate-intensity according to the potency for lowering LDL-C. High-intensity statins lowers LDL-C by 50% (atorvastatin 40<span class="elsevierStyleHsp" style=""></span>mg, atorvastatin 80<span class="elsevierStyleHsp" style=""></span>mg, rosuvastatin 20<span class="elsevierStyleHsp" style=""></span>mg and rosuvastatin 40<span class="elsevierStyleHsp" style=""></span>mg). Moderate-intensity statins lowers LDL-C 30–50% (atorvastatin 10<span class="elsevierStyleHsp" style=""></span>mg, atorvastatin 20<span class="elsevierStyleHsp" style=""></span>mg, rosuvastatin 5<span class="elsevierStyleHsp" style=""></span>mg, rosuvastatin 10<span class="elsevierStyleHsp" style=""></span>mg, simvastatin 20<span class="elsevierStyleHsp" style=""></span>mg, simvastatin 40<span class="elsevierStyleHsp" style=""></span>mg, pravastatin 40<span class="elsevierStyleHsp" style=""></span>mg, pravastatin 80<span class="elsevierStyleHsp" style=""></span>mg, lovastatin 40<span class="elsevierStyleHsp" style=""></span>mg, fluvastatin XL 80<span class="elsevierStyleHsp" style=""></span>mg, fluvastatin 40<span class="elsevierStyleHsp" style=""></span>mg bid, pitavastatin 2<span class="elsevierStyleHsp" style=""></span>mg, pitavastatin 4<span class="elsevierStyleHsp" style=""></span>mg).<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">8</span></a></p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Statistical analysis</span><p id="par0060" class="elsevierStylePara elsevierViewall">Continuous variables are expressed as the mean and standard deviation (SD) or median and interquartile range (IQR) (25th–75th percentile), according to the distribution of variables. Age was the only continuous variable with a normal distribution and was expressed as mean and SD. The others continuous variables had a non-normal distribution and were expressed as median and IQR. Categorical variables are expressed as frequencies, percentages and confidence interval of 95% (95% CI). Group comparisons were made using the Mann–Whitney <span class="elsevierStyleItalic">U</span> test or the Wilcoxon rank-sum test for continuous variables and the chi-square (<span class="elsevierStyleItalic">χ</span><span class="elsevierStyleSup">2</span>) test for categorical variables. Statistical significance was defined at <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.05. Statistical analysis was performed using SPSS™ software version 20.</p></span></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Results</span><p id="par0065" class="elsevierStylePara elsevierViewall">The study included 199 diabetic patients with a mean age of 59.0<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>9.6 years and with a preponderance (56.8%; <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>113) of males. In this population, type 2 diabetes was the predominant type of diabetes (94.0%; <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>187) and the median HbA1c were 8.0% IQR 2.2. The majority of these patients was overweight (BMI<span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>25) (77.0%; <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>131) and had a sedentary lifestyle (69.4%; <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>136). Also, we found a high prevalence of dyslipidemia (77.7%; <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>153) and hypertension (70.2%; <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>139). More than a third (33.3%; <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>66) had a previous cardiovascular event and 58.6% (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>109) were treated with statins (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0070" class="elsevierStylePara elsevierViewall">The study population was divided in two groups according to the presence or absence of previous cardiovascular event, as shown in <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>. There were no differences between the groups in terms of age, sex, metabolic control (HbA1c) and prevalence of obesity. The group of patients with previous cardiovascular events had higher prevalence of dyslipidemia (87.7 vs 72.7%; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.02), hypertension (87.9 vs 61.4%; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.0001) and was more frequently statin-treated (87.5 vs 43.4%; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.0001).</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0075" class="elsevierStylePara elsevierViewall">The group of patients without overt CVD had higher TC (178.0 vs 157.5<span class="elsevierStyleHsp" style=""></span>mg/dl; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.003), HDL-C (51.0 vs 43.0<span class="elsevierStyleHsp" style=""></span>mg/dl; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.005), LDL-C (97.0 vs 79.0<span class="elsevierStyleHsp" style=""></span>mg/dl; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.004) and non-HDL (127.0 vs 112.5<span class="elsevierStyleHsp" style=""></span>mg/dl; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.04) and higher prevalence of patients who achieved HDL-C goals (64.3 vs 33.3%; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.0001), as demonstrated in <a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>. There were no statistical differences on the median of the triglycerides and of the apo-B.</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><p id="par0080" class="elsevierStylePara elsevierViewall">A strong and positive correlation between apo-B and non-HDL-C was verified (<span class="elsevierStyleItalic">r</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.87; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001).</p><p id="par0085" class="elsevierStylePara elsevierViewall">The group of patients without overt CVD had significantly higher prevalence of patients that met the HDL-C goals (64.3 vs 33.3%; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.0001). Although, we found no statistical difference on prevalence of patients that met the LDL-C and TG goals.</p><p id="par0090" class="elsevierStylePara elsevierViewall">The study of suitability of the dose of the statin has shown that there were no differences between the groups (14.1 vs 6.6%; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.095).</p><p id="par0095" class="elsevierStylePara elsevierViewall">To evaluate the persistence of lipid abnormalities, the patients were divided in statin-treated and non-statin treated.</p><p id="par0100" class="elsevierStylePara elsevierViewall">In statin-treated patients, 13.9% were treated with statins with adequate potency to their cardiovascular profile. There were no differences between the patients with and without overt CVD in the adequacy of statin treatment (<a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a>). Less than half (46.8%, <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>44) failed to achieve the LDL-C goal. Half (51.1%; <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>48) and 35.1% (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>33) of these patients failed to achieve HDL-C and TG goals, respectively. Only 11.7% (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>11) of these patients achieved all three goals. In this group of patients, we found a statistically significant difference between those with and without cardiovascular disease in HDL-C median level (43.0 vs 50.5; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.003) and in the prevalence of patients reaching the target of HDL-C (68.1 vs 35.4%; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.001). There were no differences in the prevalence of patients who achieved LDL-C and triglyceride goals (<a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a>).</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Discussion</span><p id="par0105" class="elsevierStylePara elsevierViewall">As other similar published studies our study population included diabetic patients with a mean age in the sixties and with a high prevalence of overweight, sedentary lifestyle, dyslipidemia and hypertension.<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">9,10</span></a> Also, we found an elevated prevalence of non-statin treated patients (56.8%).</p><p id="par0110" class="elsevierStylePara elsevierViewall">The group of patients without overt CVD was more frequently non-statin treated and had higher TC, LDL-C, HDL-C and non-HDL. Also, there was a trend for statistical significance to higher apo-B levels.</p><p id="par0115" class="elsevierStylePara elsevierViewall">In the Dyslipidemia International Study (DYSIS) the diabetics without a previous CVD also had higher LDL-C and HDL-C.<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">10</span></a> Those facts may reflect better lipid-focused treatment in patients with a previous event of CVD. The group of patients without previous CVD had significantly higher prevalence of patients that achieved the HDL-C goals, and this is concordant with the findings of DYSIS.<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">10</span></a> A higher level HDL-C in patients without overt CVD can be the reflection of their cardioprotective effect.</p><p id="par0120" class="elsevierStylePara elsevierViewall">In our study, half of the statin-treated diabetic patients (53.2%) achieved LDL-C goals. This finding is similar to the analysis of Leiter et al. and Feher et al., however are in contrast with the analysis of Silva et al. of Portuguese subpopulation of the DYSIS (77.1%).<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">9–11</span></a> We verified that over one third (35.8%) did not achieved TG goals, half (51.6%) did not achieved HDL-C goals and only a minority (11.7%) of patients achieved all three goals. In the Portuguese subpopulation analysis of DYSIS the percentage of patients that not met the TG goals are similar (41.4%) but diverge on the percentage of patients that failed the HDL-C goal (27.7%).<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">9</span></a> In DYSIS, a quarter (25.9%) of the diabetic patients and almost 20% (19.9%) did not achieve TG and HDL-C goals, respectively, and 39% of the patients achieve all goals. <a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">10</span></a> Feher et al. demonstrated that approximately half of the patients who received statin monotherapy attained the treatment goals for HDL-C and TG.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">11</span></a></p><p id="par0125" class="elsevierStylePara elsevierViewall">When analyzing the suitability of the dose of the statin we verified that there were no differences between the groups, although with a tendency to significance for the group with overt CVD. This can be the expression, again, of a higher attention to lipid treatment in patients with a previous event of CVD.</p><p id="par0130" class="elsevierStylePara elsevierViewall">The vast majority of patients were treated with a dose of statin non-adequate to their cardiovascular profile. This observation must be analyzed very carefully because the study included patients observed from June 2014 to June 2015. As this recommendations were published in November 2013 by the ACC/AHH and adopted by ADA in January 2015, we cannot make firm conclusions about the suitability of statins dose, and this is a considerable limitation of the study.</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Limitations</span><p id="par0135" class="elsevierStylePara elsevierViewall">This study reflects a small sample of patients evaluated in the CTED, analyzed retrospectively and we did not evaluate long-term outcomes. In addition, we lack data of adherence to treatment regime or contraindications to statin therapy.</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Conclusion</span><p id="par0140" class="elsevierStylePara elsevierViewall">Several clinical studies have demonstrated evidence supporting the beneficial effects of statins therapy in patients for both primary and secondary prevention of CVD events and death. Also, recommendations of treatment and management of dyslipidemia are wide spread to guide medical decision. Despite those facts, evidence has shown, in concordance to our results, a suboptimal use of lipid-modifying therapies and a substantial percentage of diabetic patients that do not achieve the therapeutic goals. We emphasize that is necessary an effort to optimize the lipid profile of diabetic patients and, consequently, decrease the prevalence of CVD events in this population.</p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Ethical disclosures</span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Protection of human and animal subjects</span><p id="par0145" class="elsevierStylePara elsevierViewall">The authors declare that no experiments were performed on humans or animals for this study.</p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Confidentiality of data</span><p id="par0150" class="elsevierStylePara elsevierViewall">The authors declare that no patient data appear in this article.</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Right to privacy and informed consent</span><p id="par0155" class="elsevierStylePara elsevierViewall">The authors declare that no patient data appear in this article.</p></span></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Conflicts of interest</span><p id="par0160" class="elsevierStylePara elsevierViewall">The authors have no conflicts of interest to declare.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:13 [ 0 => array:3 [ "identificador" => "xres698526" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Introduction" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Material and methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Discussion/conclusion" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec708288" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres698527" "titulo" => "Resumo" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Introdução" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Materiais e métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Discussão e conclusão" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec708287" "titulo" => "Palavras-chave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Material and methods" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Data sources and subjects" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Data collection" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "Definition of dyslipidemia" ] 3 => array:2 [ "identificador" => "sec0030" "titulo" => "Statistical analysis" ] ] ] 6 => array:2 [ "identificador" => "sec0035" "titulo" => "Results" ] 7 => array:2 [ "identificador" => "sec0040" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0045" "titulo" => "Limitations" ] 9 => array:2 [ "identificador" => "sec0050" "titulo" => "Conclusion" ] 10 => array:3 [ "identificador" => "sec0055" "titulo" => "Ethical disclosures" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0060" "titulo" => "Protection of human and animal subjects" ] 1 => array:2 [ "identificador" => "sec0065" "titulo" => "Confidentiality of data" ] 2 => array:2 [ "identificador" => "sec0070" "titulo" => "Right to privacy and informed consent" ] ] ] 11 => array:2 [ "identificador" => "sec0075" "titulo" => "Conflicts of interest" ] 12 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2016-03-01" "fechaAceptado" => "2016-06-16" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec708288" "palabras" => array:3 [ 0 => "Diabetes mellitus" 1 => "Dyslipidemia" 2 => "Statins" ] ] ] "pt" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palavras-chave" "identificador" => "xpalclavsec708287" "palabras" => array:3 [ 0 => "Diabetes mellitus" 1 => "Dislipidemia" 2 => "Estatinas" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Introduction</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">The purposes of this study are the characterization the lipid profile and the suitability of the statins treatment according to the cardiovascular profile. Also, in statin-treated patients, we aim to determine the prevalence of persistent lipid abnormalities.</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Material and methods</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Observational and retrospective study of outpatient diabetic patients of a hospital consultation, between Jun/2014 and Jun/2015.</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Of the 199 diabetic patients included, 58.6% were treated with statins and only 13.9% were treated with statin dose adequate for its cardiovascular profile. The patients without overt cardiovascular disease had higher total cholesterol (178.0 vs 157.5<span class="elsevierStyleHsp" style=""></span>mg/dl; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.003), HDL-C (51.0 vs 43.0<span class="elsevierStyleHsp" style=""></span>mg/dl; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.005), LDL-C (97.0 vs 79.0<span class="elsevierStyleHsp" style=""></span>mg/dl; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.004) and non-HDL-C (127.0 vs 112.5<span class="elsevierStyleHsp" style=""></span>mg/dl; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.04) and higher prevalence of patients who achieved HDL-C goals (64.3 vs 33.3%; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.0001). Almost half of statin-treated patients (46.8%) failed to achieve the LDL-C goals, 35.8% and 51.6% failed the triglycerides and HDL-C goals, respectively. Only 11.7% achieved all three goals. In statin-treated patients, we found a statistically significant difference between patients with and without cardiovascular disease on the prevalence of patients reaching the target HDL-C (68.1 vs 35.4%; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.001). There were no differences in the prevalence of patients who achieved LDL-C and triglyceride goals.</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Discussion/conclusion</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">There is a suboptimal utilization of statins and a substantial percentage of diabetic patients that do not achieve the therapeutic goals. We emphasize the need for an effort to optimize the lipid profile of diabetics in order to contribute to reducing the prevalence of cardiovascular diseases in this population.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Introduction" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Material and methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Discussion/conclusion" ] ] ] "pt" => array:3 [ "titulo" => "Resumo" "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Introdução</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Os objetivos são a caracterização do perfil lipídico e a avaliação do tratamento com estatinas de acordo com o perfil cardiovascular. Adicionalmente, pretendemos determinar prevalências de anomalias lipídicas persistentes nos doentes tratados com estatinas.</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Materiais e métodos</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Estudo observacional e retrospetivo de diabéticos acompanhados numa consulta hospitalar entre 06/2014 e 06/2015.</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Dos 199 doentes, 58,6% estavam tratados com estatinas e 13,9% estavam tratados com doses de estatinas adequadas para o perfil cardiovascular. Os doentes sem doença cardiovascular (DCV) tinham níveis mais elevados de colesterol total (178,0 vs. 157,5<span class="elsevierStyleHsp" style=""></span>mg/dl; <span class="elsevierStyleItalic">p<span class="elsevierStyleHsp" style=""></span></span>=<span class="elsevierStyleHsp" style=""></span>0,003), HDL-C (51,0 vs. 43,0<span class="elsevierStyleHsp" style=""></span>mg/dl; <span class="elsevierStyleItalic">p<span class="elsevierStyleHsp" style=""></span></span>=<span class="elsevierStyleHsp" style=""></span>0,005), LDL-C (97,0 vs. 79,0<span class="elsevierStyleHsp" style=""></span>mg/dl; <span class="elsevierStyleItalic">p<span class="elsevierStyleHsp" style=""></span></span>=<span class="elsevierStyleHsp" style=""></span>0,004), e não-HDL-C (127,0 vs. 112,5<span class="elsevierStyleHsp" style=""></span>mg/dl; <span class="elsevierStyleItalic">p<span class="elsevierStyleHsp" style=""></span></span>=<span class="elsevierStyleHsp" style=""></span>0,04) e uma maior prevalência de doentes que alcançaram metas de HDL-C (64,3 vs. 33,3%; <span class="elsevierStyleItalic">p<span class="elsevierStyleHsp" style=""></span></span><<span class="elsevierStyleHsp" style=""></span>0,0001). Quase metade dos doentes tratados com estatinas (46,8%) não atingiram o valor alvo de LDL-C, 35,8 e 51,6% falharam as metas de HDL-C e de triglicerídeos, respetivamente. Apenas 11,7% atingiram todos os 3 objetivos. Nos doentes tratados com estatinas, encontramos diferença estatisticamente significativa entre os doentes com e sem DCV, sobre a prevalência de atingimento do alvo HDL-C (68,1 vs. 35,4%, p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,001). Não houve diferenças na prevalência de doentes que atingiram os objetivos de LDL-C e triglicerídeos.</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Discussão e conclusão</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Verifica-se uma utilização subótima das estatinas e uma percentagem substancial de diabéticos que não alcançam os objetivos terapêuticos. Salienta-se a necessidade de um esforço para otimizar o perfil lipídico dos diabéticos de forma a contribuir para a diminuição da prevalência de DCV nesta população.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Introdução" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Materiais e métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Discussão e conclusão" ] ] ] ] "multimedia" => array:4 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">BMI: body mass index; CAD: coronary artery disease; PAD: peripheral artery disease; T2DM: type 2 diabetes mellitus.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Variables \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Results \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Age (years), mean<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>SD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">59.0<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>9.6 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Male, %, (95% CI), (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">56.8 (47.8–63.1) (113/199) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">T2DM, %, (95% CI), (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">94.0 (89.8–96.8) (187/199) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">HbA1c (%), median; IQR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">8.0; 2.2 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Current smoker, %, (95% CI), (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">9.7 (3.8–12.7) (19/196) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Sedentary lifestyle, %, (95% CI), (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">69.4 (61.1–75.8) (136/196) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">BMI, median; IQR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">28.7; 6.3 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Overweight (BMI<span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>25 and <30), %, (95% CI), (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">38.2 (30.6–45.9) (65/170) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Obesity (BMI<span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>30), %, (95% CI), (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">38.8 32.5–47.8) (66/170) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Dyslipidemia, %, (95% CI), (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">77.7 (75.8–87.9) (153/197) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Hypertension, %, (95% CI), (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">70.2 (66.2–80.9) (139/198) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">CAD, cerebrovascular disease and/or PAD, %, (95% CI), (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">33.3 (28.0–42.7) (66/198) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Statin-treated, %, (95% CI), (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">58.6 (54.8–69.4) (109/186) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1144861.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">The characteristics of study population (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>199).</p>" ] ] 1 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at2" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">BMI: body mass index; CAD: coronary artery disease; CVD: cardiovascular disease; PAD: peripheral artery disease; T2DM: type 2 diabetes mellitus.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Variables \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Overt CVD (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>66) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Non-CVD (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>132) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">All (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>199) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">p</span> Value<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">*</span></a> \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Age (years), mean<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>SD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">60.4<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>9.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">58.2<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>9.7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">59.0<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>9.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Male, %, (95% CI) (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">54.5 (37.8–68.2) (36/66) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">58.3 (44.4–63.9) (77/132) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">56.8 (47.8–63.1) (113/199) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.6 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">T2DM, %, (95% CI) (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">98.5 (92.5–100.0) (65/66) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">91.7 (85.9–96.1) (121/132) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">94.0 (89.8–96.8) (187/199) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">HbA1c (%), median; IQR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">8.1; 2.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">8.0; 2.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">8.0; 2.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Current smoker, %, (95% CI) (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">10.6 (2.5–21.7) (7/66) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">9.2 (2.0–12.1) (12/130) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">9.7 (3.8–12.7) (19/196) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.8 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Sedentary lifestyle, %, (95% CI) (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">74.2 (69.8–93.0) (49/66) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">66.9 (57.6–75.3) (87/130) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">69.4 (61.1–75.8) (136/196) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.3 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">BMI, median; IQR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">28.9; 6.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">28.6; 6.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">28.7; 6.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.08 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Overweight (BMI ≥25 and <30), %, (95% CI) (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">46.6 (29.7–57.9) (27/58) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">33.3 (24.2–43.0) (37/111) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">38.2 (30.6–45.9) (65/170) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.09 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Obesity (BMI ≥ 30), %, (95% CI) (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">41.4 (32.6–61.4) (24/58) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">37.8 (28.6–47.4) (42/111) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">38.8 (32.5–47.8) (66/170) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.7 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Dyslipidemia, %, (95% CI) (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">87.7 (81.8–98.0) (57/65) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">72.7 (68.6–85.0) (96/132) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">77.7 (75.8–87.9) (153/197) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.02 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Hypertension, %, (95% CI) (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">87.9 (81.8–98.0) (58/66) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">61.4 (56.6–75.2) (81/132) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">70.2 (66.2–80.9) (139/198) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.0001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Statin-treated, %, (95% CI) (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">87.5 (85.4–100.0) (56/64) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">43.4 (36.3–55.8) (53/122) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">58.6 (54.8–69.4) (109/186) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.0001 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1144860.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "*" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Statistical significance: <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.05.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Characteristics of the groups: with and without overt CVD.</p>" ] ] 2 => array:8 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at3" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">CVD: cardiovascular disease.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Lipid profile \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Overt CVD \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Non-CVD \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">All \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">p</span> Value<a class="elsevierStyleCrossRef" href="#tblfn0025"><span class="elsevierStyleSup">*</span></a> \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Total cholesterol (mg/dl), median; IQR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">157.5; 51.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">178.0; 58.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">172.5; 58.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.003 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Triglycerides (mg/dl), median; IQR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">129.5; 99.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">113.0; 82.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">117.0; 85.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.3 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">HDL-C (mg/dl), median; IQR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">43.0; 14.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">51.0; 24.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">47.0; 23.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.005 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">LDL-C (mg/dl), median; IQR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">79.0; 45.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">97.0; 50.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">89.0; 49.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.004 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Apo-B (mg/dl), median; IQR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">82.0; 39.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">92.0: 33.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">90.0; 33.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.08 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Non-HDL-C (mg/dl), median; IQR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">112.5; 45.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">127.0; 53.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">117.0; 52.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.04 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Patients at LDL-C goal,<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">a</span></a> %, 95% CI, (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">39.6 (24.0–51.2) (21/53) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">52.2 (39.6–61.2) (60/115) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">48.2 (81/168) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.13 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Patients at TG goal,<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">b</span></a> %, 95% CI, (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">63.0 (47.9–76.5) (34/54) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">70.4 (61.1–80.4) (81/115) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">67.6 (115/170) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.3 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Patients at HDL-C goal,<a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">c</span></a> %, 95% CI, (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">33.3 (18.4–44.9) (18/54) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">64.3 (56.5–76.0) (74/115) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">54.1 (92/170) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.0001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Patients achieving all goals<br>(LDL-C, HDL-C and TG), %, 95% CI, (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5.7 (0.0–11.4) (3/53) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">9.6 (3.2–14.9) (11/115) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">8.3 (14/168) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Patients with adequate statin-treatment, %, 95% CI, (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">14.1 (4.5–23.9) (9/64) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6.6 (2.1 – 12.0) (8/121) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">9.1 (17/186) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.095 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1144859.png" ] ] ] "notaPie" => array:4 [ 0 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0010">LDL-C goal: <70<span class="elsevierStyleHsp" style=""></span>mg/dl and <100<span class="elsevierStyleHsp" style=""></span>mg/dl in patients with and without overt CVD, respectively.</p>" ] 1 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "b" "nota" => "<p class="elsevierStyleNotepara" id="npar0015">TG goal: <150<span class="elsevierStyleHsp" style=""></span>mg/dl.</p>" ] 2 => array:3 [ "identificador" => "tblfn0020" "etiqueta" => "c" "nota" => "<p class="elsevierStyleNotepara" id="npar0020">HDL-C goal: > 40 or 50<span class="elsevierStyleHsp" style=""></span>mg/dl, in men and women, respectively.</p>" ] 3 => array:3 [ "identificador" => "tblfn0025" "etiqueta" => "*" "nota" => "<p class="elsevierStyleNotepara" id="npar0025">Statistical significance: <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.05.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Lipid profile in diabetics with and without overt CVD.</p>" ] ] 3 => array:8 [ "identificador" => "tbl0020" "etiqueta" => "Table 4" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at4" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">CVD: cardiovascular disease.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td-with-role" title="table-head ; entry_with_role_rowhead " align="left" valign="top" scope="col">Lipid profile \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " colspan="3" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Statin-treated</th><th class="td" title="table-head " align="left" valign="top" scope="col"><span class="elsevierStyleItalic">p</span> Value<a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">*</span></a> \t\t\t\t\t\t\n \t\t\t\t</th></tr><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Overt CVD \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Non-CVD \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">All (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>109) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Adequate statin, % (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">16.1 (6.5–26.0) (9/56) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">11.5 (3.9–20.8) (6/52) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">13.9 (5.4–13.4) (15/108) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Total cholesterol (mg/dl), median; IQR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">156.0; 58.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">172.0; 53.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">162.0; 48.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.13 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Triglycerides (mg/dl), median; IQR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">134.0; 96.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">126.5; 74.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">130.0; 84.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">HDL-C (mg/dl), median; IQR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">43.0; 14.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">50.5; 18.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">45.0; 19.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.003 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">LDL-C (mg/dl), median; IQR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">77.5; 46.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">86.5; 45.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">83.0; 48.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.2 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Apo-B (mg/dl), median; IQR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">82.0; 39.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">90.0; 25.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">85.0; 30.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Non-HDL (mg/dl), median; IQR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">113.0; 50.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">115.0; 46.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">113.0; 48.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Patients not at LDL-C goal,<a class="elsevierStyleCrossRef" href="#tblfn0030"><span class="elsevierStyleSup">a</span></a> % (95% CI) (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">56.5 (35.7–67.5) (26/46) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">37.5 (24.3 – 52.4) (18/48) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">46.8 (33.7–55.4) (44/95) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.07 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Patients not at TG goal,<a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">b</span></a> % (95% CI) (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">38.3 (24.1–55.6) (18/47) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">33.3 (20.9–48.4) (16/48) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">35.8 (26.0–46.9) (34/95) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.6 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Patients not at HDL-C goal<a class="elsevierStyleCrossRef" href="#tblfn0040"><span class="elsevierStyleSup">c</span></a> % (95% CI) (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">68.1 (50.0–79.1) (32/47) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">35.4 (22.0–50.0) (17/48) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">51.6 (39.3–60.9) (49/95) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Patients achieving all goals (LDL-C, HDL-C and TG), % (n/N) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6.5 (0.0–16.7) (3/46) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">16.7 (6.8–28.0) (8/48) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">11.7 (5.7–19.8) (11/94) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.1 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1144858.png" ] ] ] "notaPie" => array:4 [ 0 => array:3 [ "identificador" => "tblfn0030" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0030">LDL-C goal: <70<span class="elsevierStyleHsp" style=""></span>mg/dl and <100<span class="elsevierStyleHsp" style=""></span>mg/dl in patients with and without overt CVD, respectively.</p>" ] 1 => array:3 [ "identificador" => "tblfn0035" "etiqueta" => "b" "nota" => "<p class="elsevierStyleNotepara" id="npar0035">TG goal: <150<span class="elsevierStyleHsp" style=""></span>mg/dl.</p>" ] 2 => array:3 [ "identificador" => "tblfn0040" "etiqueta" => "c" "nota" => "<p class="elsevierStyleNotepara" id="npar0040">HDL-C goal: > 40 or 50<span class="elsevierStyleHsp" style=""></span>mg/dl, in men and women, respectively.</p>" ] 3 => array:3 [ "identificador" => "tblfn0045" "etiqueta" => "*" "nota" => "<p class="elsevierStyleNotepara" id="npar0045">Statistical significance: <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.05.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Persistence of lipid abnormalities.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:11 [ 0 => array:3 [ "identificador" => "bib0060" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.R. Preis" 1 => "M.J. Pencina" 2 => "S.J. Hwang" 3 => "R.B. D’Agostino Sr." 4 => "P.J. Savage" 5 => "D. Levy" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/CIRCULATIONAHA.108.846519" "Revista" => array:7 [ "tituloSerie" => "Circulation" "fecha" => "2009" "volumen" => "120" "numero" => "3" "paginaInicial" => "212" "paginaFinal" => "220" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19581493" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0065" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Task Force" 1 => "L. Ryden" 2 => "P.J. Grant" 3 => "S.D. Anker" 4 => "C. Berne" 5 => "F. Cosentino" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/eurheartj/eht108" "Revista" => array:7 [ "tituloSerie" => "Eur Heart J" "fecha" => "2013" "volumen" => "34" "numero" => "39" "paginaInicial" => "3035" "paginaFinal" => "3087" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23996285" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0070" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lipid control in patients with diabetes mellitus" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "D.J. Betteridge" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/nrcardio.2011.23" "Revista" => array:7 [ "tituloSerie" => "Nat Rev Cardiol" "fecha" => "2011" "volumen" => "8" "numero" => "5" "paginaInicial" => "278" "paginaFinal" => "290" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21403658" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0075" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diabetic dyslipidemia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "L. Wu" 1 => "K.G. Parhofer" 2 => "dyslipidemia. Diabetic" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Metab: Clin Exp" "fecha" => "2014" "volumen" => "63" "numero" => "12" "paginaInicial" => "1469" "paginaFinal" => "1479" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0080" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Kotseva" 1 => "D. Wood" 2 => "G. De Backer" 3 => "D. De Bacquer" 4 => "K. Pyorala" 5 => "U. Keil" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Eur J Cardiovasc Prevent Rehab: Off J Eur Soc Cardiol, Epidemiol Prevent Cardiac Rehabil Exerc Physiol" "fecha" => "2009" "volumen" => "16" "numero" => "2" "paginaInicial" => "121" "paginaFinal" => "137" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0085" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.K. Gitt" 1 => "H. Drexel" 2 => "J. Feely" 3 => "J. Ferrieres" 4 => "J.R. Gonzalez-Juanatey" 5 => "K.K. Thomsen" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Eur J Prevent Cardiol" "fecha" => "2012" "volumen" => "19" "numero" => "2" "paginaInicial" => "221" "paginaFinal" => "230" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0090" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Standards of medical care in diabetes – 2014. Diabetes Care. 2014; 37 Suppl 1:S14-80. Epub 2013/12/21." ] ] ] 7 => array:3 [ "identificador" => "bib0095" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Standards of medical care in diabetes – 2015: summary of revisions. Diabetes Care. 2015;38 Suppl:S4. Epub 2014/12/30." ] ] ] 8 => array:3 [ "identificador" => "bib0100" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Persistent lipid abnormalities in statin-treated patients: Portuguese diabetic subpopulation of the Dyslipidaemia International Study (DYSIS)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "P.M. da Silva" 1 => "S.M. Cardoso" 2 => "A.M. Ferreira" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Prim Care Diab" "fecha" => "2015" "volumen" => "9" "numero" => "4" "paginaInicial" => "283" "paginaFinal" => "289" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0105" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "L.A. Leiter" 1 => "P. Lundman" 2 => "P.M. da Silva" 3 => "H. Drexel" 4 => "C. Junger" 5 => "A.K. Gitt" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1464-5491.2011.03360.x" "Revista" => array:7 [ "tituloSerie" => "Diabet Med" "fecha" => "2011" "volumen" => "28" "numero" => "11" "paginaInicial" => "1343" "paginaFinal" => "1351" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21679231" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0110" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "M. Feher" 1 => "M. Greener" 2 => "N. Munro" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2147/DMSO.S35053" "Revista" => array:6 [ "tituloSerie" => "Diabetes Metab Syndr Obes" "fecha" => "2013" "volumen" => "6" "paginaInicial" => "11" "paginaFinal" => "15" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23341741" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/16463439/0000001100000002/v1_201607230344/S1646343916300232/v1_201607230344/en/main.assets" "Apartado" => array:4 [ "identificador" => "19188" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Artigos originais" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/16463439/0000001100000002/v1_201607230344/S1646343916300232/v1_201607230344/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1646343916300232?idApp=UINPBA00004N" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 0 | 1 | 1 |
2024 October | 107 | 14 | 121 |
2024 September | 161 | 8 | 169 |
2024 August | 103 | 13 | 116 |
2024 July | 104 | 10 | 114 |
2024 June | 87 | 14 | 101 |
2024 May | 93 | 11 | 104 |
2024 April | 65 | 19 | 84 |
2024 March | 104 | 18 | 122 |
2024 February | 135 | 12 | 147 |
2024 January | 77 | 14 | 91 |
2023 December | 67 | 15 | 82 |
2023 November | 43 | 9 | 52 |
2023 October | 70 | 15 | 85 |
2023 September | 66 | 10 | 76 |
2023 August | 38 | 17 | 55 |
2023 July | 32 | 13 | 45 |
2023 June | 26 | 4 | 30 |
2023 May | 35 | 10 | 45 |
2023 April | 42 | 6 | 48 |
2023 March | 24 | 1 | 25 |
2023 February | 26 | 7 | 33 |
2023 January | 19 | 6 | 25 |
2022 December | 30 | 9 | 39 |
2022 November | 40 | 14 | 54 |
2022 October | 62 | 16 | 78 |
2022 September | 35 | 17 | 52 |
2022 August | 51 | 18 | 69 |
2022 July | 34 | 11 | 45 |
2022 June | 40 | 13 | 53 |
2022 May | 64 | 9 | 73 |
2022 April | 68 | 14 | 82 |
2022 March | 103 | 12 | 115 |
2022 February | 112 | 6 | 118 |
2022 January | 79 | 13 | 92 |
2021 December | 66 | 7 | 73 |
2021 November | 78 | 10 | 88 |
2021 October | 44 | 18 | 62 |
2021 September | 25 | 15 | 40 |
2021 August | 23 | 10 | 33 |
2021 July | 12 | 5 | 17 |
2021 June | 27 | 15 | 42 |
2021 May | 19 | 10 | 29 |
2021 April | 59 | 17 | 76 |
2021 March | 31 | 12 | 43 |
2021 February | 22 | 11 | 33 |
2021 January | 18 | 8 | 26 |
2020 December | 23 | 14 | 37 |
2020 November | 25 | 9 | 34 |
2020 October | 19 | 10 | 29 |
2020 September | 36 | 13 | 49 |
2020 August | 27 | 11 | 38 |
2020 July | 35 | 11 | 46 |
2020 June | 26 | 12 | 38 |
2020 May | 32 | 11 | 43 |
2020 April | 26 | 12 | 38 |
2020 March | 27 | 8 | 35 |
2020 February | 38 | 14 | 52 |
2020 January | 35 | 6 | 41 |
2019 December | 23 | 6 | 29 |
2019 November | 31 | 8 | 39 |
2019 October | 26 | 11 | 37 |
2019 September | 23 | 13 | 36 |
2019 August | 33 | 8 | 41 |
2019 July | 37 | 9 | 46 |
2019 June | 44 | 20 | 64 |
2019 May | 69 | 23 | 92 |
2019 April | 56 | 9 | 65 |
2019 March | 96 | 6 | 102 |
2019 February | 93 | 9 | 102 |
2019 January | 83 | 3 | 86 |
2018 December | 93 | 1 | 94 |
2018 November | 92 | 6 | 98 |
2018 October | 159 | 6 | 165 |
2018 September | 85 | 3 | 88 |
2018 August | 53 | 24 | 77 |
2018 July | 30 | 12 | 42 |
2018 June | 44 | 10 | 54 |
2018 May | 33 | 10 | 43 |
2018 April | 78 | 18 | 96 |
2018 March | 106 | 36 | 142 |
2018 February | 68 | 23 | 91 |
2018 January | 33 | 16 | 49 |
2017 December | 57 | 27 | 84 |
2017 November | 44 | 17 | 61 |
2017 October | 49 | 19 | 68 |
2017 September | 53 | 20 | 73 |
2017 August | 50 | 18 | 68 |
2017 July | 46 | 12 | 58 |
2017 June | 71 | 29 | 100 |
2017 May | 65 | 33 | 98 |
2017 April | 41 | 24 | 65 |
2017 March | 37 | 14 | 51 |
2017 February | 41 | 21 | 62 |
2017 January | 36 | 18 | 54 |
2016 December | 49 | 29 | 78 |
2016 November | 53 | 43 | 96 |
2016 October | 52 | 23 | 75 |
2016 September | 32 | 21 | 53 |
2016 August | 29 | 25 | 54 |
2016 July | 16 | 25 | 41 |